Roivant Posts $4.3B Cash, $2.25B Moderna Deal and 73% ACR20 Response
Roivant reported $4.3B cash as of March 31, 2026 and expects $950M upfront from a $2.25B Moderna settlement in July. Q4 clinical data showed 73% ACR20 response in its 1,402 trial, and it secured breakthrough designation for PrEP/Sitnib while preparing brevacitinib launch by September.
1. Financial Position
Roivant ended Q4 2025 with $4.3 billion in cash and no debt, bolstered by a $2.25 billion settlement with Moderna that will deliver $950 million upfront in July. The company also maintains an active share repurchase program and has increased R&D spending to support its expanding program scope.
2. Clinical Trial Results
Roivant’s 1,402 study in rheumatic disease showed 73% of patients achieving ACR20, with over 50% hitting ACR50 and over 33% reaching ACR70, underlining strong efficacy. The firm also secured a breakthrough therapy designation for its PrEP/Sitnib candidate for retinitis sarcoidosis.
3. Pipeline and Regulatory Outlook
Roivant plans an FDA decision on brevacitinib for dermatomyositis by September, preparing for a potential commercial launch. Challenges include failed betokumab trials in TED, unpowered Phase 2 Mosley data on the six-minute walk test, and ongoing analysis of patient-level data to define regulatory strategies.